Adjuvant Radiotherapy with Three-Dimensional Conformal Radiotherapy of XXXX .

@entity1 @entity146 @entity5 @entity2347 @entity1442 @entity3
BACKGROUND _ AIM: @entity2347 ( @entity2347 ) of lacrimal gland is a rare @entity5 with @entity146 . There is sparse data to address optimum therapy for such @entity5 . So, the present study was aimed at evaluating the role of adjuvant three dimensional conformal radiotherapy (3D-CRT) in cases of incomplete (R1) resection along with review of literature pertaining to management of lacrimal @entity2347 . MATERIALS AND METHODS: We retrospectively reviewed the demographic and treatment data of 10 biopsy proven @entity2347 of lacrimal gland @entity1 , treated from December 2006 to June 2013. They were treated with radiotherapy following surgical resection. Eight @entity1 underwent gross total excision of the @entity5 mass (enbloc excision) followed by conformal radiotherapy to a dose of 60 Gray/30fractions/ 6 weeks. Two @entity1 with @entity1442 were treated with palliative radiotherapy after biopsy. RESULTS: The median age was 32 years. There were equal numbers of male and female @entity1 . The median duration of symptoms was 7 months. At a median follow up of 21 months, eight @entity1 had no evidence of disease and had complete @entity5 response, two @entity1 worsened, and one of the two had systemic failure with bone @entity3 . CONCLUSION: Despite a small sample size and short follow, enbloc surgical excision with adjuvant radiotherapy is well tolerated and shows good control in @entity2347 of lacrimal gland.
